Chemotherapy of high-grade astrocytomas

Handbook of Brain Tumor Chemotherapy

Volumn , Issue , 2006, Pages 347-363

  Newton, Herbert B ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882823481     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088410-0/50062-7     Document Type: Chapter

References (125)

1. Newton H.B. Primary brain tumors: Review of etiology, diagnosis, and treatment. Am Fam Phys 1994, 49:787-797.
2. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neurooncol 2002, 4:278-299.
3. ACS (American Cancer Society) Cancer Facts and Figures 2002 2002, American Cancer Society, Atlanta.
4. Kleihues P., Louis D.N., Scheithauer B.W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215-225.
5. Salcman M. Malignant glioma management. Neurosurg Clin N Am 1990, 1:49-64.
6. Dunn I.F., Black P.M. The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy. Neurosurg 2003, 52:1411-1424.
7. Matz P.G., Cobbs C., Berger M.S. Intraoperative cortical mapping as a guide to the surgical resection of gliomas. J Neurooncol 1999, 42:233-245.
8. Lemole G.M., Henn J.S., Riina H.A., Spetzler R.F. Cranial application of frameless stereotaxy. BNI Quart 2001, 17:16-24.
9. Nimsky C., Ganslandt O., Kober H., Buchfelder M., Fahlbusch R. Intraoperative magnetic resonance imaging combined with neuronavigation: A new concept. Neurosurg 2001, 48:1082-1091.
10. DeVaux B.C., O'Fallon J.R., Kelly P.J. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 2001, 78:767-775.
11. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198.
12. Shrieve D.C., Loeffler J.S. Advances in radiation therapy for brain tumors. Neurol Clin 1995, 13:773-794.
13. Miyamoto C. Radiation therapy principles for high-grade gliomas. Combined Modality Therapy of Central Nervous System Tumors 2001, Vol. 18:345-364. Springer. Z. Petrovich, L.W. Brady, M.L. Apuzzo, M. Bamberg (Eds.).
14. Laperriere N., Zuraw L., Cairncross J.G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64:259-273.
15. Chang E.L., Yi W., Allen P.K., Levin V.A., Sawaya R.E., Maor M.H. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: Outcome and prognostic factors. Int J Rad Oncol Biol Phys 2003, 56:519-528.
16. Roa W., Brasher P.M.A., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004, 22:1583-1588.
17. Selker R.G., Shapiro W.R., Burger P., et al. The Brain Tumor Cooperative Group, N. I., H trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurg 2002, 51:343-357.
18. Nwokedi E., DiBiase S.J., Jabbour S., Herman J., Amin P., Chin L.S. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurg 2002, 50:41-47.
19. Prisco F.E., Weltman E., Hanriot R.M., Brandt R.A. Radiosurgical boost for primary high-grade gliomas. J Neurooncol 2002, 57:151-160.
20. Kornblith P.L., Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988, 68:1-17.
21. Kyritsis A.P. Chemotherapy for malignant gliomas. Oncol 1993, 7:93-100.
22. Brandes A.A., Fiorentino M.V. The role of chemotherapy in recurrent malignant gliomas: An overview. Cancer Investig 1996, 14:551-559.
23. Pech I.V., Peterson K., Cairncross J.G. Chemotherapy for brain tumors. Oncol 1998, 12:537-547.
24. Cokgor I., Friedman H.S., Friedman A.H. Chemotherapy for adults with malignant glioma. Cancer Investig 1999, 17:264-272.
25. Fine H.A. The basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994, 20:111-120.
26. Macdonald D.R., Cascino T.L., Schold S.C., Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
27. Garrett M.J., Hughes H.J., Freeman L.S. A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 1978, 4:71-76.
28. Eagan R.T., Childs D.S., Layton D.D., et al. Dianhydrogalactitol and radiation therapy: treatment of supratentorial glioma. JAMA 1979, 24:2046-2050.
29. Solero C.L., Monfardini S., Brambilla C., et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979, 1979:43-48.
30. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
31. Green S.B., Byar D.P., Walker M.D., et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983, 67:121-132.
32. Deutsch M., Green S.B., Strike T.A., et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU followin misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Rad Oncol Biol Phys 1989, 16:1389-1396.
33. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 1989, 71:1-9. Brain Tumor Cooperative Group trial 8001.
34. Shapiro W.R., Green S.B., Burger P.C., et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992, 76:772-781.
35. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Rad Oncol Biol Phys 2004, 60:853-860.
36. Levin V.A., Silver P., Hannigan J., et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Rad Oncol Biol Phys 1990, 18:321-324.
37. Prados M.D., Scott C., Curran W.J., Nelson D.F., Leibel S., Karmer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999, 17:3389-3395.
38. Fine H.A., Dear K.B.G., Loeffler J.S., Black P.M., Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
39. Steward L.A., Burdett S., Souhami R.L., Stenning S. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
40. Rosen E.M., Fan S., Rockwell S., Goldberg I.D. The molecular and cellular basis of radiosensitivity: Implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Investig 1999, 17:56-72.
41. Colevas A.D., Brown J.M., Hahn S., Mitchell J., Camphausen K., Coleman C.N. Development of investigational radiation modifiers. J Natl Cancer Inst 2003, 95:646-651.
42. Vokes E.E., Weichselbaum R.R. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990, 8:911-934.
43. Devine S.M., Vokes E.E., Weichselbaum R.R. Chemotherapeutic and biologic radiation enhancement. Curr Opin Oncol 1991, 3:1087-1095.
44. Haraf D.J., Weichselbaum R.R., Vokes E.E. Timing and sequencing of chemoradiotherapy. Cancer Treat Res 1995, 74:173-198.
45. Masters G.A., Vokes E.E. Radiotherapy and concomitant chemotherapy. Encyclopedia of Cancer 1997, Volume III:1471-1480. Academic Press, Berlin. J.R. Bertino (Ed.).
46. Glantz M.J., Kim L., Choy H., Akerley W. Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncol 1999, 13:78-82.
47. Goffman T.E., Dachowski L.J., Bobo H., et al. Long-term follow-up on National Cancer Institute phase I/II study of glioblastoma multiforme treated with iododeoxy-uridine and hyperfractionated irradiation. J Clin Oncol 1992, 10:264-268.
48. Werner-Wasik M., Scott C.B., Nelson D.F., et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Cancer 1996, 77:1535-1543. Radiation Therapy Oncology Group study 83-02.
49. Urtasun R.C., Kinsella T.J., Farnan N., Del Rowe J.D., Lester S.G., Fulton D.S. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, phase I-II study. Int J Rad Oncol Biol Phys 1996, 36:1163-1167.
50. Chen A.Y., Choy H., Rothenburg M.L. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncol 1999, 13:39-46.
51. Grabenbauer G.G., Anders K., Fietkau R.J., et al. Prolonged infusional topotecan and accelerated hyperfractinated 3d-conformal radiation in patients with newly diagnosed glioblastoma - a phase I study. J Neurooncol 2002, 60:269-275.
52. Rowinsky E.K. Novel radiation sensitizers targeting tissue hypoxia. Oncol 1999, 13:61-70.
53. Del Rowe J., Scott C., Werner-Wasik M., et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 2000, 18:1254-1259.
54. Kleinberg L., Grossman S.A., Carson K., et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II New Approaches to Brain Tumor Therapy CNS Consortium safety and efficacy study. J Clin Oncol 2002, 20:3149-3155.
55. Stevens M.F.G., Newlands E.S. From triazines and triazenes to temozolomide. Eur J Cancer 1993, 20A:1045-1047.
56. Newlands E.S., O'Reilly S.M., Glaser M.G., et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996, 32A:2236-2241.
57. Newlands E.S., Stevens M.F.G., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61.
58. Hvizdos K.M., Goa K.L. Temozolomide. CNS Drugs 1999, 12:237-243.
59. Friedman H.S., Kerby T., Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000, 6:2585-2597.
60. Stupp R., Gander M., Leyvraz S., Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001, 2:552-560.
61. Danson S.J., Middleton M.R. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001, 1:13-19.
62. Wedge S.R., Porteous J.K., Glaser M.G., et al. In vitro evaluation of temozolomide combined with x-irradiation. Anticancer Drugs 1997, 8:92-97.
63. van Rijn J., Heimans J.J., van den Berg J., et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Rad Oncol Biol Phys 2000, 47:779-784.
64. Hirose Y., Berger M.S., Pieper R.O. P53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61:1957-1963.
65. Stupp R., Dietrich P.Y., Kraljevic S.O., et al. Promising survival for patients with newly diagnosed glioblastoma treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382.
66. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005, 352:987-996.
67. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005, 352:997-1003.
68. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
69. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
70. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005, 23:2372-2377.
71. Chang S.M., Lamborn K.R., Malec M., et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Rad Oncol Biol Phys 2004, 60:353-357.
72. Dropcho E.J., Rosenfeld S.S., Morawetz R.B., et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J Clin Oncol 1992, 10:452-458.
73. Bottom K.S., Ashley D.M., Friedman H.S., et al. Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2000, 46:151-156.
74. Weller M., Streffer J., Wick W., et al. Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. Cancer 2001, 91:423-427.
75. Wick W., Hermisson M., Kortmann R.D., et al. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma. A phase II study. J Neurooncol 2002, 59:151-155.
76. Puchner M.J.A., Herrmann H.D., Berger J., Cristante L. Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neurooncol 2000, 49:147-155.
77. Friedman H.S., McLendon R.E., Kerby T., et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16:3851-3857.
78. Gilbert M.R., Friedman H.S., Kuttesch J.F., et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neurooncol 2002, 4:261-267.
79. Glantz M., Chamberlain M., Liu Q., Litofsky N.S., Recht L.D. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant glioma. Cancer 2003, 97:2262-2266.
80. Chinot O.L., Barrie M., Frauger E., et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100:2208-2214.
81. Newlands E.S., Foster T., Zaknoen S. Phase I study of temozolomide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 2003, 89:248-251.
82. Chang S.M., Prados M.D., Yung W.K.A., et al. Phase II study of neoadjuvant 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma. A North American Brain Tumor Consortium trial. Cancer 2004, 100:1712-1716.
83. Balaña C., López-Pousa A., Berrocal A., et al. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). J Neurooncol 2004, 70:359-369.
84. Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council Trial. J Clin Oncol19, 509-518.
85. Reni M., Cozzarini C., Ferreri A.J.M., et al. A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme. Cancer Investig 2000, 18:510-515.
86. Jeremic B., Jovanivic D., Djuric L.J., Jevremovic S., Mijatovic L.J. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J Chemother 1992, 4:123-126.
87. Levin V.A., Uhm J.H., Jaeckle K.A., et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-choroethyl)-N'-cyclohexyl-N-nitrosourea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000, 6:3878-3884.
88. Levin V.A., Hess K.R., Choucair A., et al. Phase III randomized study of postradiotherapy chemotherapy with combination -difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003, 9:981-990.
89. Chibbaro S., Benvenuti L., Caprio A., et al. Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol 2004, 67:77-81.
90. Raizer J.J., Malkin M.G., Kleber M., Abrey L.E. Phase I study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neurooncol 2004, 6:247-252.
91. Baumann F., Bjeljac M., Kollias S.S., et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004, 67:191-200.
92. Newton H.B., Junck L., Bromberg J., Page M.A., Greenberg H.S. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurol 1990, 40:1743-1746.
93. Newton H.B., Bromberg J., Junck L., Page M.A., Greenberg H.S. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neurooncol 1993, 15:257-263.
94. Spence A.M., Berger M.S., Livinston R.B., Ali-Osman F., Griffin B. Phase II evaluation of high-dose cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neurooncol 1992, 12:187-191.
95. Yung W.K.A., Mechtler L., Gleason M.J. Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol 1991, 9:860-864.
96. Jeremic B., Grujicic D., Jevremovic S., et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 1992, 10:1074-1077.
97. Tirelli U., D'Incalci M., Canetta R., et al. Etoposide (VP-16-213) in malignant brain tumors: A phase II study. J Clin Oncol 1984, 2:432-437.
98. Fulton D., Urtasun R., Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant gliomas. J Neurooncol 1996, 27:149-155.
99. Chamberlain M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002, 56:183-188.
100. Cloughesy T.F., Filka E., Nelson G., et al. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol 2002, 25:204-208.
101. Chamberlain M.C., Tsao-Wei D.D. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 2004, 100:1213-1220.
102. Couldwell W.T., Hinton D.R., Surnock A.A., et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996, 2:619-622.
103. Chamberlain M.C., Kormanik P.A. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999, 56:703-708.
104. Huncharek M., Muscat J. Treatment of recurrent high grade astrocytoma; Results of a systematic review of 1,415 patients. Anticancer Res 1998, 18:1303-1312.
105. Huncharek M., Kupelnick B., Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 1998, 24:307-316.
106. Yung W.K.A., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999, 17:2762-2771.
107. Yung W.K.A., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
108. Osoba D., Brada M., Yung W.K.A., Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000, 18:1481-1491.
109. Macdonald D.R., Kiebert G., Prados M., Yung W.K.A., Olson J. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: Effect on neurological functioning, performance status, and health related quality of life. Cancer Investig 2005, 23:138-144.
110. Chang S.M., Theodosopoulos P., Lamborn K., et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004, 100:605-611.
111. Everaert E., Neyns B., Joosens E., Strauven T., Branle F., Menten J. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol 2004, 70:37-48.
112. Khan R.B., Raizer J.J., Malkin M.G., Bazylewicz K.A., Abrey L.E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neurooncol 2002, 4:39-43.
113. Schold S.C., Kuhn J.G., Chang S.M., et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study. Neurooncol 2000, 2:34-39.
114. Prados M.D., Yung W.K.A., Fine H.A., et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neurooncol 2004, 6:33-37.
115. Korones D.N., Benita-Weiss M., Coyle T.E., et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 2003, 97:1963-1968.
116. Gururangan S., Cokgor K., Rich J.N., et al. Phase I study of Giadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neurooncol 2001, 3:246-250.
117. Gruber M.L., Buster W.P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 2004, 27:33-38.
118. Brandes A.A., Basso U., Reni M., et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperative di Neuro-Oncologia. J Clin Oncol 2004, 22:1598-1604.
119. Groves M.D., Puduvalli V.K., Hess K.R., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
120. Jaeckle K.A., Hess K.R., Yung W.K.A., et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol 2003, 21:2305-2311.
121. Chua S.L., Rosenthal M.A., Wong S.S., et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neurooncol 2004, 6:38-43.
122. Spence A.M., Peterson R.A., Scharnhorst J.D., Selbergeld D.L., Rostomily R.C. Phase II study of concurrent continuous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 2004, 70:91-95.
123. Newton H.B. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 1-growth factor and ras signaling pathways. Expert Rev Anticancer Ther 2003, 3:595-614.
124. Newton H.B. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 2-PI3K/Akt/PTEN, mTOR, SHH/PTCH, and angiogenesis. Expert Rev Anticancer Ther 2004, 4:105-128.
125. Newton H.B. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 5-apoptosis and cell cycle. Expert Rev Anticancer Ther 2005, 5:355-378.